Cite Filings / AVTX / 0001193125-26-220002
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13G

Statement of Beneficial Ownership

Avalo Therapeutics, Inc. · Filed 2026-05-12 · Acc 0001193125-26-220002

Documents 1

  • SCHEDULE 13G Statement of Beneficial Ownership , xslSCHEDULE_13G_X02/primary_doc.xml

Around this filing

  • 2026-05-15 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-05-14 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2026-05-13 10-Q Quarterly Report
  • 2026-05-13 8-K Results of operations
  • 2026-05-12 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-05-11 4 Chief Financial Officer sold 18,606 shares at $24.12 ($448,818)
  • 2026-04-01 SCHEDULE 13G Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · BVF PARTNERS L P/IL 1.7%
  2. 2026-11-16 SCHEDULE 13G/A · Point72 Asset Management, L.P. 3.0%
  3. 2026-11-13 SCHEDULE 13G · Farallon Capital Management, L.L.C. 7.4%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…